Brokers Issue Forecasts for Qiagen’s Q4 Earnings (NYSE:QGEN)

Qiagen N.V. (NYSE:QGEN) – Research analysts at Zacks Research boosted their Q4 2026 earnings per share (EPS) estimates for Qiagen in a research report issued to clients and investors on Wednesday, February 25th. Zacks Research analyst Team now anticipates that the company will earn $0.66 per share for the quarter, up from their prior forecast of $0.63. The consensus estimate for Qiagen’s current full-year earnings is $2.26 per share. Zacks Research also issued estimates for Qiagen’s Q1 2027 earnings at $0.67 EPS and Q4 2027 earnings at $0.77 EPS.

A number of other equities research analysts have also recently commented on QGEN. Citigroup reduced their target price on shares of Qiagen from $55.40 to $55.00 and set a “neutral” rating for the company in a research report on Friday, February 6th. JPMorgan Chase & Co. increased their price objective on shares of Qiagen from $55.00 to $60.00 and gave the company an “overweight” rating in a report on Friday, February 6th. UBS Group set a $52.00 target price on shares of Qiagen in a research note on Monday, February 9th. Wall Street Zen upgraded Qiagen from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Finally, Stifel Nicolaus set a $50.00 price target on Qiagen and gave the company a “hold” rating in a report on Friday, February 6th. Four equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $55.20.

Qiagen Trading Down 2.3%

Shares of QGEN stock opened at $47.70 on Monday. Qiagen has a fifty-two week low of $39.61 and a fifty-two week high of $57.81. The company has a debt-to-equity ratio of 0.44, a quick ratio of 3.31 and a current ratio of 3.90. The stock’s fifty day moving average is $50.01 and its two-hundred day moving average is $49.29. The firm has a market capitalization of $10.07 billion, a P/E ratio of 23.66, a PEG ratio of 2.38 and a beta of 0.70.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Thursday, February 5th. The company reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.01. Qiagen had a return on equity of 14.56% and a net margin of 20.33%.The firm had revenue of $540.42 million for the quarter, compared to analyst estimates of $528.53 million. During the same period in the previous year, the company posted $0.61 earnings per share. The business’s revenue was up 3.6% on a year-over-year basis.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in QGEN. United Services Automobile Association purchased a new stake in Qiagen in the first quarter valued at $239,000. Envestnet Asset Management Inc. increased its position in shares of Qiagen by 26.6% during the 2nd quarter. Envestnet Asset Management Inc. now owns 425,396 shares of the company’s stock worth $20,439,000 after purchasing an additional 89,301 shares during the last quarter. Atria Investments Inc raised its holdings in Qiagen by 2.9% in the 2nd quarter. Atria Investments Inc now owns 7,674 shares of the company’s stock valued at $369,000 after buying an additional 218 shares during the period. Amalgamated Bank lifted its position in Qiagen by 1.8% in the second quarter. Amalgamated Bank now owns 11,751 shares of the company’s stock valued at $565,000 after buying an additional 209 shares during the last quarter. Finally, Simon Quick Advisors LLC purchased a new position in Qiagen during the second quarter worth about $208,000. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.